info:eu-repo/semantics/article
Biodistribution of the boron carriers boronophenylalanine (BPA) and/or decahydrodecaborate (GB-10) for Boron Neutron Capture Therapy (BNCT) in an experimental model of lung metastases
Fecha
2013-12Registro en:
Trivillin, Verónica Andrea; Garabalino, Marcela Alejandra; Colombo, Lucas Luis; González, Sara Josefina; Farías, Rubén Oscar; et al.; Biodistribution of the boron carriers boronophenylalanine (BPA) and/or decahydrodecaborate (GB-10) for Boron Neutron Capture Therapy (BNCT) in an experimental model of lung metastases; Elsevier; Applied Radiation and Isotopes; 88; 12-2013; 94-98
0969-8043
CONICET Digital
CONICET
Autor
Trivillin, Verónica Andrea
Garabalino, Marcela Alejandra
Colombo, Lucas Luis
González, Sara Josefina
Farías, Rubén Oscar
Monti Hughes, Andrea
Pozzi, Emiliano César Cayetano
Bortolussi, Silva
Altieri, S.
Itoiz, María Elina
Aromando, Romina Flavia
Nigg, D. W.
Schwint, Amanda Elena
Resumen
BNCT was proposed for the treatment of diffuse, non-resectable tumors in the lung. We performed boron biodistribution studies with 5 administration protocols employing the boron carriers BPA and/or GB-10 in an experimental model of disseminated lung metastases in rats. All 5 protocols were non-toxic and showed preferential tumor boron uptake versus lung. Absolute tumor boron concentration values were therapeutically useful (25–76 ppm) for 3 protocols. Dosimetric calculations indicate that BNCT at RA-3 would be potentially therapeutic without exceeding radiotolerance in the lung.